Objective: To reexamine the relationship of hospital and surgical volume to all-cause and breast cancer-specific mortality, taking into account the potential selection bias in patients treated at high-volume centers or by high-volume surgeons.
A number of studies, including a meta-analysis of 12 goodquality recent studies, have now demonstrated better survival among breast cancer patients treated by higher volume providers. 1 Conducted in 6 different countries, these studies have shown about 16%-20% lower risk of dying over the first 5 years after surgery for patients treated by high-volume surgeons or in high-volume hospitals, compared with those treated by low-volume providers. The interpretation of these findings has typically been that the better survival of patients of highvolume providers is attributable to the greater experience and proficiency afforded by a larger number of cases.
This explanation is intuitive and attractive, but it is not the only explanation for a relationship between higher volume of cases and better outcomes. A plausible alternative is selection bias in the patients treated at high-volume centers or by high-volume surgeons, that is, that patients at lower risk of poor outcomes are more likely to be treated by high-volume providers. For breast cancer, this selection bias has been demonstrated to exist. For example, breast cancer patients treated at low-volume hospitals are poorer, more likely nonwhite, less well educated, and are more likely to have Medicaid insurance. 2 Each of these factors has a negative effect on overall survival, and could represent a confounder for evaluating the relationship between volume of cases and outcome of care. Despite this potential for selection bias, no study supporting the breast cancer volume-outcome relationship has been randomized in design. 1 The available studies have been based almost entirely on observational databases without individual-level information available on sociodemographic characteristics or economic status.
When evaluating observational data, 1 way to determine whether results are robust to selection bias is to use an alternative outcome, and to determine whether the results are consistent with expectations. For example, in previous studies involving breast cancer, we used death from breast cancer as an alternative outcome to overall survival, expecting that the volume-outcome relationship would be stronger for the outcome of breast cancer deaths, compared with the outcome of overall survival. 3, 4 Another method for dealing with selection bias is to employ a specific analytic technique designed for this purpose, instrumental variable (IV) analysis. This method, originally arising from the economic literature, yields results generally free of selection bias, even for unobserved confounders. [5] [6] [7] Surprisingly, this method has been rarely used in volume-outcome studies to date despite the observational nature of this literature.
The purpose of this study is to evaluate the relationship of hospital volume and surgeon volume of breast cancer cases to survival, using IV techniques to address potential selection biases. If the relationship were found to persist using IV methods, this would support organizational initiatives to promote better breast cancer outcomes. One potential initiative is regionalization of breast cancer care. Despite the existing literature, little regionalization has taken place with regard to breast cancer care in the United States, and case volumes for many US hospitals and surgeons remain substantially below the volumes in many European countries. 1 Another potential initiative would be determining what processes lead to better outcomes by high-volume providers, and disseminating those practices more widely.
METHODS

Study Population and Data Sources
The main data source for the study was the "Improving the Care and Outcomes of Women Undergoing Breast Surgery," a population-based, longitudinal survey of communitydwelling elderly women with incident breast cancer. The study sample consisted of elderly women in 4 geographic and racially diverse states-California, Florida, Illinois, and New York-identified from Medicare claims as having had surgery for incident, early-stage (SEER 2000 stage <3) breast cancer between April and September of 2003. 8 Potentially eligible participants were contacted by phone in early 2005 to confirm the breast cancer diagnosis and to conduct the first of 4 annual structured telephone interviews (See Supplemental Digital Appendix for details on survey design and methods, Supplemental Digital Content 1, http://links.lww.com/MLR/ B28). Survey data were supplemented by information from Medicare Denominator and claims data, State Tumor Registry data, Census, and Area Resource File data.
The cohort for this study consisted of the 2408 women whose incident breast cancer surgery was performed at a hospital within the 4 study states, and for which hospital volume of breast cancer cases could be calculated from the state-wide Medicare data.
Outcome Measures
The key outcomes for this study were 5-year all-cause and breast cancer-specific mortality. Because CMS only provided us with information for patients who were alive at the time of recruitment, only deaths occurring after study entry could be ascertained. For all study participants, 5-year all-cause mortality was obtained from CMS Vital Statistics regardless of study completion. Cause of death was obtained from a linkage to the National Death Index (Centers for Disease Control and Prevention).
Hospital and Surgeon Volume
Hospital volume was calculated based on the annual average for the 24-month period preceding each patient's incident surgery in 2003 for the universe of Medicare breast cancer incident cases in each study state, following the methodology used in prior work. 3, 4 Hospitals were then classified based on percentile cutoffs of Medicare breast cancer patients in the 4 study states. As a point of departure, hospitals were categorized as high volume if they performed 40+ Medicare breast cancer surgeries annually, a threshold roughly corresponding to the upper tertile of cases, used previously to identify high-volume breast cancer hospitals in the United States. 3 We refer to this group of hospitals as "moderately high volume" hospitals. In an alternative classification, hospitals were categorized as high volume if they performed >81 Medicare breast cancer surgeries per year, corresponding to the upper decile of all incident breast cancer surgeries among Medicare beneficiaries. This cutoff corresponds more closely to the literature from the UK, Ireland, Canada, and Taiwan, as these countries exhibit a greater degree of regionalization of breast cancer care than does the United States. 1 Surgeon volume was measured based on the universe of Medicare breast cancer incident case surgeries performed by the surgeon during the 12-month period preceding the woman's surgery. Patients were then classified as being treated by a "moderately high volume" surgeon if they were treated by surgeons performing 12 or more Medicare breast cancer surgeries per year (upper tertile) and, alternatively, as treated by a "high volume" surgeon if treated by surgeons performing 28 or more Medicare breast cancer surgeries per year (upper decile). Again, these cutoffs correspond to those used previously in the US literature (upper tertile), and to those more comparable with the literature outside the United States (upper decile).
Other Covariates
Each subject's address was geocoded to classify all beneficiaries into Census tracts. All hospitals in the study states were geocoded based on the American Hospital Association Survey to determine the latitude and longitude coordinates. Using these coordinates, we ascertained each woman's distance to the closest hospital and distance to the closest moderately high-volume hospital.
Information about the patient's sociodemographic background was obtained primarily from patient surveys. Women were classified according to their reported race/ ethnicity as white non-Hispanic, black/African American non-Hispanic, Hispanic, or other race/ethnicity. Marital status categories were married/living with a partner, widowed, separated/divorced, and never married. Educational level was captured by years of formal education and categorized as less than high school, high school graduate, and some college. Respondents were also asked to estimate their annual household income in the year preceding the initial survey. Income was then classified in categories as missing income, $15,000 or less, $15,001-$30,000, $30,001-$45,000, and >$45,000 (reference category). Social support was assessed using the Medical Outcomes Study Social Support Scale. 9 Women were coded as having low social support if they scored at the lowest quartile of the distribution for both emotional/informational and tangible support scales. Control variables were measured at study entry and, to the extent possible, reflect the patient's circumstances at the time of the incident breast cancer surgery.
Tumor stage information (SEER 2000) was obtained from the 4 state tumor registries. Comorbidity was measured based on inpatient, outpatient, and Carrier Medicare data for the year preceding the incident breast cancer surgery based on the Klabunde algorithm. 10 Finally, certain key structural small-area socioeconomic and health market supply characteristics, including proportion of adult population in poverty and unemployment in the patient's county of residence, as well as density of surgeons and density of general physicians, were created based on data from the Area Resource File.
Statistical Analyses
Key to the analysis was methods to reduce the likelihood of bias based on differential patient self-selection to high-volume providers. An IV analysis was employed. [5] [6] [7] Following the TwoStage Residual Inclusion estimation proposed by Terza et al, 11 in the first stage of the analysis, the probability that a breast cancer patient would choose a hospital (or surgeon) based on its case volume of breast cancer surgery, measured alternatively as "moderately high volume" (top tertile) or "high volume" (top decile) versus all others, was estimated using a Probit specification. The IV method requires that (instrumental) variables be included in stage 1 that are predictive of women's hospital choice but do not independently affect mortality. Our choice of IVs was guided by the robust research indicating that geographic proximity to providers is an important determinant of the choice of high-volume provider. 12, 13 We employed as key instruments 2 distance measures: distance to the nearest hospital and distance to the nearest high-volume hospital. We also examined the potential of certain supply variables, for example, density of surgeons, density of general physicians, and number of community breast cancer centers, as instruments in our models. For all analyses, we tested the validity of our instruments using Stock and Staiger test based on the partial R 2 and Chow F-statistics on the excluded variables in the first-stage regression. 14 In the second stage of the IV analysis, a Probit regression was employed to compute adjusted probabilities of all-cause death or death from breast cancer, using as covariates the treatment at a high-volume hospital (surgeon), the residuals from the first-stage estimation, as well as the demographic, economic, disease, and ecological factors included in the first-stage analysis. Here again, the adequacy of the instruments was tested with respect to the extent to which they could be legitimately excluded from the mortality estimations, conditional on hospital (surgeon) volume and firststage residuals. In both stages, SEs were adjusted to account for potential clustering (multiple patients within hospitals).
All statistical analyses were performed using STATA 12 (College Station, TX) and NLOGIT 9.0 statistical software (Econometric Software Inc., Plainview, NY).
RESULTS
Women in this sample of 2408 Medicare beneficiaries with incident breast cancer were predominantly white ( Table 1) . The racial distribution reflected the racial makeup of Medicare beneficiaries in these states as well as the predilection of breast cancer for white women. Slightly fewer than half were married. Although about half had attended at least some college, the mean household income was slightly below $30,000 for the 80% of the cohort who reported this information. About half of the sample reported low levels of social support. Most (56.7%) had stage 1 disease and no comorbid conditions. Less than 2% of the sample had advanced disease (SEER stage Z3). Women lived an average of 5 miles from the nearest hospital, but an average of 42 miles from the nearest moderately high-volume hospital and 84 miles from the nearest high-volume hospital. The all-cause mortality over the average 33 months of follow-up was 7.1%, and breast cancer-specific mortality was 2.5%.
Factors Associated With Treatment at High-Volume Hospitals
Increasing age was associated with a trend toward a lower likelihood of undergoing surgery at a high-volume hospital (Table 2) . Compared with the poorest women, those with higher household incomes or with missing income information were considerably more likely to undergo surgery at a high-volume hospital. Women residing in counties with a greater percentage of the population living in poverty had a greater chance of treatment in a high-volume hospital, whereas women residing in a county with higher unemployment had a significantly lower chance of treatment in a high-volume hospital. Disease stage, minority status, educational attainment, and marital status were not associated with treatment at a high-volume hospital, when controlling for other measures of socioeconomic status. The IVs-distance to the nearest hospital and distance to the nearest high-volume hospital-performed well as measured by the tests of adequacy of the instruments, with highly significant F-statistics of 17.3 (P < 0.01) and 11.3 (P < 0.01), respectively, for top decile and top tertile highvolume hospitals. Greater distance to the nearest high-volume hospital was associated with a much lower likelihood of treatment at such a hospital. Although the full models are not presented for treatment by a moderately high or high-volume surgeon, the IVs performed well in those models as well, with F-statistics at 18.5 (P < 0.01) and 12.2 (P < 0.01), respectively, demonstrating the validity of these factors as IVs. 14 
Hospital Volume, Surgeon Volume, and 5-Year Mortality
In the fully instrumented model, which also controlled for demographic, socioeconomic, and extent of disease factors, women treated in high-volume hospitals were significantly less likely to die of any cause by 5 years after surgery (Table 3 ). For breast cancer-specific mortality, this relationship was even stronger, with a larger effect size and stronger statistical significance. Although the general pattern of better mortality outcomes held when the more conventional definition of high volume (top tertile) was used, the high-volume coefficient estimates were smaller in magnitude and did not achieve statistical significance. The IV analyses for surgeon volume revealed no relationship of surgeon volume with all-cause or breast cancer-specific mortality, whether volume was defined as moderately high (top tertile) or high (top decile) volume. Models estimated using a Probit specification. Statistically significant differences at the **Pr0.05 and *0.05 < Pr0.10 levels. Hospitals were classified as moderately high volume if they ranked at the top tertile of annual Medicare cases (hospitals performing >40 Medicare incident breast cancer cases per year) during the 24 months preceding the subjects' incident surgery; the conventional classification of high-volume hospitals in the US hospitals were classified as high-volume hospitals, the subset of the moderately high hospitals that rank in the top decile of annual Medicare cases (> 81 Medicare cases per year) during the 24 months preceding the subject's incident surgery. Reference category for race/ethnicity is non-African American, non-Hispanic (primarily white) women; for marital status is unmarried; for education is some college; for household income is <$15,000 per year; for disease stage is stage 1; for state of treatment is California.
To illustrate the magnitude of the effect of treatment in a high-volume hospital, we used the parameter estimates from our models to estimate the adjusted excess all-cause mortality attributable to treatment in hospitals other than the high-volume hospitals. We found that if women had been treated at a lower volume hospital, the predicted probability of death at 5 years was 8.9% compared with 1.1% had they been treated at a high-volume hospital.
DISCUSSION
In this survey study of 2408 women with incident, early-stage breast cancer, those operated upon in high-volume hospitals were significantly less likely to die from any cause at 5 years, when using IV methods to control for the substantial differences in the types of patients seen in high volume versus other hospitals. Women treated in high-volume hospitals were also significantly less likely to die from breast cancer. The magnitude of the protective effect of treatment in a high-volume facility was quite substantial, certainly as much as the benefit conferred by many systemic therapies, as women simulated to receive treatment in lower volume facilities had an 8-fold higher likelihood of death at 5 years than women treated at a high-volume facility. There were no all-cause or breast cancer-specific survival differences when hospital volume was defined by the conventional, broader categorization of high volume (top tertile) in the US literature. Similarly, surgeon case volume had no relationship to 5-year mortality when using an IV analysis to control for the differences in types of patients treated by high-volume surgeons.
Our results are in partial agreement with the prior literature on case volume and outcomes for breast cancer. Much of the prior literature, as well as the meta-analysis, 1 finds that both surgeon and hospital case volume is positively related to overall survival among breast cancer patients, as opposed to our finding that only hospital case volume is related to survival. Our findings suggest that selection bias is a more likely explanation for the relationship between surgeon case volume and outcome. 4 The findings of this study highlight the importance of addressing the issue of self-selection to higher volume providers of patients destined to do better. 15 Much of the prior literature on volume-outcome relationship has been based on administrative data analyses. 3, 4, [16] [17] [18] [19] [20] [21] [22] [23] [24] Such databases may not offer the opportunity to fully control for the bias of selfselection to higher volume providers. 25 There is rationale to the finding that hospital volume is associated with better mortality outcomes, whereas surgeon volume is not. Breast cancer surgery is not a highly morbid procedure, with in-hospital mortality rates in the range of 0.1%-0.2%. 26 Therefore, purely technical expertise of the surgeon is a less likely explanation for patient differences in 5-year survival, unlike other cancer 27 or noncancer 28 surgeries. For breast cancer, it is more likely that better processes of care account for the better observed outcomes. Hospitals with high case volumes have more incentive to invest in the development of better care processes. These processes are as yet undetermined, but might include, for example, case management (care navigators), more systematic use of multidisciplinary care, or better ancillary care.
This study has limitations, including the fact that entry into the cohort required survival to the first survey interview, roughly 27 months after incident surgery. Although such a lag raises concerns about survival bias, evidence suggests that early breast cancer mortality is relatively low among women with incident disease. Using 2002-2004 data from the National Cancer Database (NCDB), we estimated 12-and 24-month all-cause mortality among women with incident breast cancer to be 1.7% and 4.3%, respectively. Given that: (i) breast cancer mortality comprises about 30% of all-cause mortality among women with incident breast cancer; 4 (ii) these NCDB mortality estimates include women with advanced stage disease who were not part of our study; and (iii) early, 30-day breast cancer mortality is relatively evenly distributed across hospitals of varying volumes, 1 it is unlikely that survival bias is a significant practical concern in our study. Nonetheless, our findings must be interpreted in light of this limitation. The results are limited to 5-year, and not longer term, mortality. However, as the outcome becomes more distant in time, the likelihood of being able to ascribe outcomes to the care received around the time of the surgery becomes more and more difficult. Finally, the analyses were based on an older cohort of patients who agreed to participate in our survey, and not an unconditional all-age cohort. However, there were no significant differences between elderly women who were contacted and those who opted to participate in the study, 8 and previous analyses have shown a strong relationship between a provider's volume of cases in the Medicare age group and the volume of cases overall. 3 *Statistically significant coefficients at the P < 0.05 level. Hospitals were classified as moderately high volume if they ranked at the top tertile of annual Medicare cases (hospitals performing >40 Medicare incident breast cancer cases per year) during the 24 months preceding the subjects' incident surgery. Hospitals were classified as high-volume hospitals, the subset of the moderately high hospitals that rank in the top decile of annual Medicare cases (> 81 Medicare cases per year) during the 24 months preceding the subject's incident surgery. For surgeon volume, the thresholds for top tertile and top decile were Z12 and Z28 annual incident breast cancer surgeries during the 12-month period preceding the woman's surgery, respectively. Models also control for sociodemographic, economic, extent of disease factors, and first-stage residuals. See Supplemental Digital Appendix for the full set of coefficient estimates (Supplemental Digital Content 1, http://links.lww.com/MLR/B28).
The existing literature has led at least 2 government entities to enact policies designed to promote regionalization of breast cancer surgery. In 2009, the New York State Department of Health set forth a policy mandating that Medicaid beneficiaries receive breast cancer surgery at centers that perform at least 30 of these procedures annually. 29 In 2007, The French Ministry of Health and Solidarity issued a decree mandating that hospitals treating breast cancer be able to demonstrate performance of at least 30 of these procedures annually. 30 In addition, the UK requires that breast cancer providers meet certain minimum case volumes. 31 Using NCDB data of all patients with incident breast cancer in 2008, we plotted the location of high-volume hospitals and their corresponding 100-mile driving distances on a map of the United States to examine the feasibility of regionalization of breast cancer care. As evident in Figure 1 , large portions of the country are not within a 100-mile driving distance of a high-volume hospital, particularly in the western and plains states, a finding that raises concerns about implementing such policy initiatives in the United States.
In summary, the 5-year all-cause and breast cancerspecific survival of women with early-stage incident breast cancer could be improved if more women were treated in high-volume hospitals. The magnitude of the potential improvement in survival is quite substantial, certainly as much as the benefit conferred by many systemic therapies. As women of minority race and women of lower socioeconomic status are less likely than others to live close to a high-volume hospital, 2 regionalization of care might also improve the rather large existing disparities in breast cancer survival for such women. Large parts of the country are not within a 100-mile driving distance of a current high-volume facility, but policies to promote regionalization of care would be expected to produce a greater number of high-volume facilities. Further research to determine which care processes most account for the better outcomes of the high-volume hospitals could also improve outcomes in lower volume facilities.
